In Brief: Centocor
This article was originally published in The Gray Sheet
Executive Summary
Centocor: National Institutes of Health is contemplating granting firm an exclusive, worldwide license for use of KAI1 monoclonal antibodies in diagnostic/prognostic fields for prostate cancer, and is seeking comments/other applications by Oct. 10. Patent rights have been assigned to the U.S. and Johns Hopkins University; the license would be royalty-bearing. For further information, contact Joseph Hemby, Jr., in NIH's Office of Technology Transfer at 301/496-7735, ext. 265...